Remidex Pharma Private Limited - Due diligence report

A 360° intelligence report on Remidex Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals…

1981-06-15 Bengaluru, Karnataka Active Unlisted Active Compliant
Share
RP Remidex Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Remidex Pharma — 360° Intelligence Report

Generated from MCA filings & public records
72/100
Trust Score
Moderate

Remidex Pharma is assessed as Moderate with a Trust Score of 72/100. Remidex Pharma is an active private limited indian non-government company incorporated in 1981, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.

Report generated on 21 Jul 2026 from the latest processed filings. Remidex Pharma Private Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
72/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
68/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
35/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 38%).
  • Externally credit-rated (B).

Charges position: 1 open (4.00 cr) · 8 satisfied (15.26 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Canara Bank5 48.0 cr
Others1 48.0 cr
Kotak Mahindra Bank Limited2 48.0 cr
Kotak Mahindra Bank Ltd1 48.0 cr
Compliance Score: 68/100 Moderate
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 2 court forum(s).
  • 1 auditor resignation(s) filed - latest: B.Shivananda Pai & Co. on 2022-11-19.
  • Delayed payments to MSME suppliers disclosed (10 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
ISHAAN PEJAVAR RAO 01234567 Director 01/04/2018 6 yrs Approved
NANDAN PEJAVAR RAO 01234567 Director 01/04/2018 6 yrs Approved
NILIMA DAYANAND RAO 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 3 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: NILIMA DAYANAND RAO (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 90
Growth signals & trust indicators
Operating for 45+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 4.69 Lakh.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence76/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment46/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 4.00 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view46/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
20 Jan 2022
Charge satisfied
Canara Bank
19 Jun 2020
Charge satisfied
Canara Bank
11 Jun 2020
Director ceased
MOHINI DAYANAND RAO
Charge satisfied
Others
31 Mar 2020
Share transfer (FY 2020)
500.00000000 shares to ISHAAN PEJAVAR RAO
Share transfer (FY 2020)
500.00000000 shares to NANDAN PEJAVAR RAO
Share transfer (FY 2020)
248313.00000000 shares to NILIMA DAYANAND RAO
24 Sep 2019
Director ceased
ISHAAN PEJAVAR RAO
Director ceased
NANDAN PEJAVAR RAO
21 Aug 2019
Charge created
Others - 6.00 cr
22 Dec 2018
Director ceased
VENKATRAM SUBRAMONY
05 Dec 2018
Director ceased
GIRISH CHANDRA
29 Oct 2018
Director ceased
ANNASAGARAM BALAGURUNATH RAMKUMAR
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of B from Brickwork.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Gmk Labs Private Limited U24239TG2006PTC051554 Secunderabad, Telangana, India
Linux Life Sciences U74900PY2015PTC002951 Pondicherry, Pondicherry, India
Anphar Organics Private Limited. U24231JK1994PTC001409 Jammu, Jammu & Kashmir, India
Inwac Metals And Chemicals Pvt Ltd U74999MH1984PTC031888 Mumbai, Maharashtra, India
Nexus Pharma Chem Private Limited U24231GJ2002PTC040850 Ahmedabad, Gujarat, India
Kim Laboratories Pvt Ltd U74899HR1982PTC013796 Haryana, Haryana, India
Biomax Biotechnics U24100CH2009PTC031718 Chandigarh, Chandigarh, India
Uniza Lifecare Private Limited U24230GJ2020PTC113820 Kadi, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Remidex Pharma before audits and certifications: compliance score 68/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Remidex Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Remidex Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 72/100, distress signals and MSME payment-delay disclosures - know whether Remidex Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Remidex Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Remidex Pharma an active company?

Remidex Pharma has MCA status “Active” with a compliance score of 68/100 (Moderate).

Is Remidex Pharma financially healthy?

Remidex Pharma has a Financial Health Score of 35/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Remidex Pharma?

Its overall Trust Score is 72/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Remidex Pharma?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Remidex Pharma have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 8 earlier charge(s) stand satisfied.

Is Remidex Pharma up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 68/100 (Moderate).

Is it risky to lend to Remidex Pharma?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.